Stock TSPC PT TEMPO SCAN PACIFIC TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Tempo Scan Pacific Tbk

Equities

TSPC

ID1000104508

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
2,060 IDR -0.96% Intraday chart for PT Tempo Scan Pacific Tbk +3.52% +12.26%
05-01 PT Tempo Scan Pacific Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-28 PT Tempo Scan Pacific Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 6,255,000 6,277,500 6,300,000 6,764,796 6,358,909 8,275,601
Enterprise Value (EV) 1 4,816,403 4,540,048 4,335,777 4,918,675 4,222,487 5,522,412
P/E ratio 12.2 x 11.3 x 8 x 8.2 x 6.35 x 7.03 x
Yield 2.88% 3.58% 4.29% 4.67% 8.87% -
Capitalization / Revenue 0.62 x 0.57 x 0.57 x 0.6 x 0.52 x 0.63 x
EV / Revenue 0.48 x 0.41 x 0.4 x 0.44 x 0.34 x 0.42 x
EV / EBITDA 5.31 x 4.46 x 3.33 x 3.79 x 4.52 x 4.09 x
EV / FCF -43.2 x 10.3 x 11.8 x 42.2 x 324 x 7.43 x
FCF Yield -2.32% 9.71% 8.48% 2.37% 0.31% 13.5%
Price to Book 1.22 x 1.14 x 1.04 x 1.04 x 0.88 x 1.08 x
Nbr of stocks (in thousands) 4,500,000 4,500,000 4,500,000 4,509,864 4,509,864 4,509,864
Reference price 2 1,390 1,395 1,400 1,500 1,410 1,835
Announcement Date 29/03/19 01/04/20 31/03/21 31/03/22 24/03/23 28/03/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 10,088,119 10,993,842 10,968,402 11,234,443 12,254,369 13,119,785
EBITDA 1 907,580 1,017,689 1,301,141 1,297,800 933,588 1,350,964
EBIT 1 702,576 797,080 1,075,647 1,104,347 728,658 1,079,831
Operating Margin 6.96% 7.25% 9.81% 9.83% 5.95% 8.23%
Earnings before Tax (EBT) 1 727,700 796,221 1,064,449 1,098,370 1,329,823 1,603,164
Net income 1 512,029 554,263 787,803 823,768 1,001,628 1,177,432
Net margin 5.08% 5.04% 7.18% 7.33% 8.17% 8.97%
EPS 2 113.8 123.2 175.1 183.0 222.0 261.0
Free Cash Flow 1 -111,501 440,624 367,844 116,568 13,021 743,613
FCF margin -1.11% 4.01% 3.35% 1.04% 0.11% 5.67%
FCF Conversion (EBITDA) - 43.3% 28.27% 8.98% 1.39% 55.04%
FCF Conversion (Net income) - 79.5% 46.69% 14.15% 1.3% 63.16%
Dividend per Share 2 40.00 50.00 60.00 70.00 125.0 -
Announcement Date 29/03/19 01/04/20 31/03/21 31/03/22 24/03/23 28/03/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,438,597 1,737,452 1,964,223 1,846,122 2,136,422 2,753,189
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -111,501 440,624 367,844 116,568 13,021 743,613
ROE (net income / shareholders' equity) 10.3% 10.6% 13.7% 13.2% 14.4% 16%
ROA (Net income/ Total Assets) 5.74% 6.13% 7.69% 7.36% 4.34% 5.96%
Assets 1 8,923,315 9,035,767 10,240,386 11,188,395 23,064,631 19,753,246
Book Value Per Share 2 1,142 1,219 1,346 1,448 1,600 1,707
Cash Flow per Share 2 423.0 501.0 588.0 596.0 773.0 819.0
Capex 1 466,219 328,688 447,837 385,870 592,167 326,651
Capex / Sales 4.62% 2.99% 4.08% 3.43% 4.83% 2.49%
Announcement Date 29/03/19 01/04/20 31/03/21 31/03/22 24/03/23 28/03/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT TEMPO SCAN PACIFIC TBK Stock PT Tempo Scan Pacific Tbk
+12.26% 582M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 693B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 584B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 372B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 211B
NOVARTIS AG Stock Novartis AG
+10.02% 210B
AMGEN INC. Stock Amgen Inc.
+8.49% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TSPC Stock
  4. Financials PT Tempo Scan Pacific Tbk